|
1
|
Thai AA, Solomon BJ, Sequist LV, Gainor JF
and Heist RS: Lung cancer. Lancet. 398:535–554. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Provencio M, Nadal E, Insa A,
García-Campelo MR, Casal-Rubio J, Dómine M, Majem M,
Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, et al:
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell
lung cancer (NADIM): An open-label, multicentre, single-arm, phase
2 trial. Lancet Oncol. 21:1413–1422. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wakelee H, Liberman M, Kato T, Tsuboi M,
Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, et al:
Perioperative pembrolizumab for early-stage non-small-cell lung
cancer. N Engl J Med. 389:491–503. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sorin M, Prosty C, Ghaleb L, Nie K,
Katergi K, Shahzad MH, Dubé LR, Atallah A, Swaby A, Dankner M, et
al: Neoadjuvant chemoimmunotherapy for NSCLC: A systematic review
and meta-analysis. JAMA Oncol. 10:621–633. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Travis WD, Dacic S, Wistuba I, Sholl L,
Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, et
al: IASLC multidisciplinary recommendations for pathologic
assessment of lung cancer resection specimens after neoadjuvant
therapy. J Thorac Oncol. 15:709–740. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cottrell TR, Thompson ED, Forde PM, Stein
JE, Duffield AS, Anagnostou V, Rekhtman N, Anders RA, Cuda JD,
Illei PB, et al: Pathologic features of response to neoadjuvant
anti-PD-1 in resected non-small-cell lung carcinoma: A proposal for
quantitative immune-related pathologic response criteria (irPRC).
Ann Oncol. 29:1853–1860. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hou Z, Zhao L, Zou L and Li B: The
prognostic value of tumor-infiltrating lymphocytes in non-small
cell lung cancer patients who received neoadjuvant chemotherapy
followed by surgery. Adv Clin Exp Med. 32:847–853. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yan Q, Li S, He L and Chen N: Prognostic
implications of tumor-infiltrating lymphocytes in non-small cell
lung cancer: A systematic review and meta-analysis. Front Immunol.
15:14763652024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fischer K, Hoffmann P, Voelkl S,
Meidenbauer N, Ammer J, Edinger M, Gottfried E, Schwarz S, Rothe G,
Hoves S, et al: Inhibitory effect of tumor cell-derived lactic acid
on human T cells. Blood. 109:3812–3819. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tetzlaff MT, Messina JL, Stein JE, Xu X,
Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross
MI, et al: Pathological assessment of resection specimens after
neoadjuvant therapy for metastatic melanoma. Ann Oncol.
29:1861–1868. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rizzo A, Mollica V, Santoni M, Palmiotti G
and Massari F: Pathologic complete response in urothelial carcinoma
patients receiving neoadjuvant immune checkpoint inhibitors: A
meta-analysis. J Clin Med. 11:10382022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Symmans WF, Peintinger F, Hatzis C, Rajan
R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, et
al: Measurement of residual breast cancer burden to predict
survival after neoadjuvant chemotherapy. J Clin Oncol.
25:4414–4422. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Forde PM, Spicer J, Lu S, Provencio M,
Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson
SJ, et al: Neoadjuvant nivolumab plus chemotherapy in resectable
lung cancer. N Engl J Med. 386:1973–1985. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chaft JE, Oezkan F, Kris MG, Bunn PA,
Wistuba II, Kwiatkowski DJ, Owen DH, Tang Y, Johnson BE, et al:
Neoadjuvant atezolizumab for resectable non-small cell lung cancer:
An open-label, single-arm phase II trial. Nat Med. 28:2155–2161.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dacic S: Neoadjuvant therapy and lung
cancer: Role of pathologists. Arch Pathol Lab Med. 149:e78–e81.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Weissferdt A, Leung CH, Lin H, Sepesi B,
William WN, Swisher SG, Cascone T, Lee JJ and Pataer A: Pathologic
processing of lung cancer resection specimens after neoadjuvant
therapy. Mod Pathol. 37:1003532024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Alì G, Poma AM, Di Stefano I, Zirafa CC,
Lenzini A, Martinelli G, Romano G, Chella A, Baldini E, Melfi F and
Fontanini G: Different pathological response and histological
features following neoadjuvant chemotherapy or chemo-immunotherapy
in resected non-small cell lung cancer. Front Oncol.
13:11151562023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu Z, Gao Z, Zhang M, Wang X, Gong J,
Jiang S and Zhang Z: Real-world effectiveness and prognostic
factors analysis of stages I–III non-small cell lung cancer
following neoadjuvant chemo-immunotherapy or neoadjuvant
chemotherapy. Ann Thorac Cardiovasc Surg. 28:111–120. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kalvapudi S, Vedire Y, Yendamuri S and
Barbi J: Neoadjuvant therapy in non-small cell lung cancer: Basis,
promise, and challenges. Front Oncol. 13:12861042023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bankhead P, Loughrey MB, Fernández JA,
Dombrowski Y, McArt DG, Dunne PD, McQuaid S, Gray RT, Murray LJ,
Coleman HG, et al: QuPath: Open source software for digital
pathology image analysis. Sci Rep. 7:168782017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pataer A, Kalhor N, Correa AM, Raso MG,
Erasmus JJ, Kim ES, Behrens C, Lee JJ, Roth JA, Stewart DJ, et al:
Histopathologic response criteria predict survival of patients with
resected lung cancer after neoadjuvant chemotherapy. J Thorac
Oncol. 7:825–832. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kadota K, Nitadori JI, Sima CS, Ujiie H,
Rizk NP, Jones DR, Adusumilli PS and Travis WD: Tumor spread
through air spaces is an important pattern of invasion and impacts
the frequency and location of recurrences after limited resection
for small stage I lung adenocarcinomas. J Thorac Oncol. 10:806–814.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ma R, Yang H, Ge Y, Ma T, Wang J, Li S,
Feng T, Feng S, Zhang C, Sun T, et al: Prognostic implications of
lymph node status in non-small-cell lung cancer patients before and
after neoadjuvant chemoimmunotherapy: A multicenter retrospective
study. Clin Lung Cancer. 26:370–383. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chiappetta M, Tabacco D, Iaffaldano AG,
Evangelista J, Congedo MT, Sassorossi C, Meacci E, D'Argento E,
Bria E, Vita E, et al: Clinical stage III NSCLC patients treated
with neoadjuvant therapy and surgery: The prognostic role of nodal
characteristics. Life (Basel). 12:17532022.PubMed/NCBI
|
|
25
|
Huang S, Wu J, Li S, Li X, Zeng R, Tang Y,
Tang J, Ben X, Zhang D, Xie L, et al: Evaluation of combined
pathological responses in primary tumor and lymph nodes following
neoadjuvant chemoimmunotherapy in non-small cell lung cancer. Lung
Cancer. 186:1074012023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rojas F, Parra ER, Wistuba II, Haymaker C
and Solis Soto LM: Pathologic response and immune biomarker
assessment in non-small-cell lung carcinoma receiving neoadjuvant
immune checkpoint inhibitors. Cancers (Basel). 14:27752022.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim S, Lee J and Chung JH: Histological
assessment and interobserver agreement in major pathologic response
for non-small cell lung cancer with neoadjuvant therapy. Cancer Res
Treat. 57:401–411. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Banna GL, Hassan MA, Signori A, Giunta EF,
Maniam A, Anpalakhan S, Acharige S, Ghose A and Addeo A:
Neoadjuvant chemo-immunotherapy for early-stage non-small cell lung
cancer: A systematic review and meta-analysis. JAMA Netw Open.
7:e2468372024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Junker K, Thomas M, Schulmann K, Klinke F,
Bosse U and Müller KM: Tumour regression in non-small-cell lung
cancer following neoadjuvant therapy. Histological assessment. J
Cancer Res Clin Oncol. 123:469–477. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Elsner F, Kümpers C, Ott G, Döring J,
Schildknecht K, Fisseler-Eckhoff A, von Laffert M, Baier L, Giulini
L, Kraus D, et al: Current practice of pathologic response
assessment following chemoimmunotherapy for non-small cell lung
cancer (NSCLC) in Germany: First real-world data from the
multicentre Re-GraDE study. Histopathology. 87:869–879. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nie F, Wang Y, Shi W, Zhu L, Hao J and Tao
R: Prognosis prediction using significant pathological response
following neoadjuvant immunotherapy in resectable non-small-cell
lung tumors: A meta-analysis. Front Surg. 11:15005932024.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Qu Y, Emoto K, Eguchi T, Aly RG, Zheng H,
Chaft JE, Tan KS, Jones DR, Kris MG, Adusumilli PS and Travis WD:
Pathologic assessment after neoadjuvant chemotherapy for NSCLC:
Importance and implications of distinguishing adenocarcinoma from
squamous cell carcinoma. J Thorac Oncol. 14:482–493. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang H, Niu X, Jin Z, Zhang S, Fan R, Xiao
H and Hu SS: Immunotherapy resistance in non-small cell lung
cancer: From mechanisms to therapeutic opportunities. J Exp Clin
Cancer Res. 44:2502025. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu C, Chen Y, Xu X, Yin M, Zhang H and Su
W: Utilizing macrophages missile for sulfate-based nanomedicine
delivery in lung cancer therapy. Research (Wash D C).
7:04482024.PubMed/NCBI
|
|
35
|
Zhao L, Li M, Shen C and Luo Y, Hou X, Qi
Y, Huang Z, Li W, Gao L, Wu M and Luo Y: Nano-assisted radiotherapy
strategies: New opportunities for treatment of non-small cell lung
cancer. Research (Wash D C). 7:04292024.PubMed/NCBI
|
|
36
|
Roy SF, Louie AV, Liberman M, Wong P and
Bahig H: Pathologic response after modern radiotherapy for
non-small cell lung cancer. Transl Lung Cancer Res. 8 (Suppl
2):S124–S134. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Huynh C, Sorin M, Rayes R, Fiset PO, Walsh
LA and Spicer JD: Pathological complete response as a surrogate
endpoint after neoadjuvant therapy for lung cancer. Lancet Oncol.
22:1056–1058. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dacic S, Travis WD, Giltnane JM, Kos F,
Abel J, Hilz S, Fujimoto J, Sholl L, Ritter J, Khalil F, et al:
Artificial intelligence-powered assessment of pathologic response
to neoadjuvant atezolizumab in patients with NSCLC: Results from
the LCMC3 study. J Thorac Oncol. 19:719–731. 2024. View Article : Google Scholar : PubMed/NCBI
|
